XNCR
Xencor, Inc. NASDAQ Listed Dec 3, 2013$12.31
Mkt Cap $902.8M
52w Low $6.92
45.8% of range
52w High $18.69
50d MA $12.29
200d MA $12.31
P/E (TTM)
-10.2x
EV/EBITDA
-27.0x
P/B
1.5x
Debt/Equity
0.3x
ROE
-14.5%
P/FCF
-8.2x
RSI (14)
—
ATR (14)
—
Beta
0.99
50d MA
$12.29
200d MA
$12.31
Avg Volume
767.5K
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.
111 West Lemon Avenue · Pasadena, CA 91016 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | -0.75 | -1.71 | -129.0% | 13.01 | -2.8% | -5.4% | — | — | — | — | — |
| Feb 25, 2026 | AMC | -0.64 | -0.09 | +85.9% | 11.98 | +3.8% | +13.1% | -5.8% | -3.7% | -2.3% | +6.0% | — |
| Nov 5, 2025 | AMC | -0.72 | -0.08 | +88.9% | 14.37 | +0.2% | -2.6% | -0.7% | -1.2% | +8.2% | -3.2% | — |
| Aug 6, 2025 | AMC | -0.78 | -0.41 | +47.4% | 7.49 | +2.1% | -2.3% | -1.2% | -3.2% | +10.7% | -0.4% | — |
| May 7, 2025 | AMC | -0.63 | -0.66 | -4.8% | 7.99 | -1.8% | +10.0% | -5.2% | +5.3% | -7.5% | +0.4% | — |
| Feb 27, 2025 | AMC | -0.81 | -0.62 | +23.5% | 14.98 | +0.0% | +2.5% | -5.9% | -2.1% | -1.8% | -0.4% | — |
| Nov 6, 2024 | AMC | -0.98 | -0.71 | +27.6% | 22.68 | +0.7% | +2.2% | +1.9% | -1.3% | +1.7% | -0.4% | — |
| Aug 5, 2024 | AMC | -0.85 | -1.07 | -25.9% | 17.78 | -1.4% | +0.4% | -12.0% | +2.3% | -0.1% | -1.5% | — |
| May 9, 2024 | AMC | -0.76 | -1.11 | -46.1% | 23.54 | +0.2% | -4.5% | -5.1% | -4.6% | +4.6% | +5.5% | — |
| Feb 27, 2024 | AMC | 0.36 | -0.31 | -186.1% | 26.52 | -7.7% | -14.1% | +0.7% | +3.8% | +0.4% | -4.5% | — |
| Nov 7, 2023 | AMC | -0.77 | -0.40 | +48.1% | 18.54 | -1.9% | -7.0% | -4.1% | +3.2% | -0.1% | +8.3% | — |
| Aug 3, 2023 | AMC | -0.91 | -0.37 | +59.3% | 23.35 | +7.8% | +3.6% | +0.3% | -1.6% | -3.3% | +0.9% | — |
| May 8, 2023 | AMC | -0.75 | -1.02 | -36.0% | 27.34 | -4.5% | -1.9% | +0.2% | -0.7% | +0.2% | +4.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 24 | JP Morgan | Downgrade | Overweight → Neutral | — | $12.05 | $11.37 | -5.6% | -1.3% | +4.3% | -0.7% | -7.2% | -0.6% |
| Feb 26 | Barclays | Maintains | Overweight → Overweight | — | $11.98 | $12.43 | +3.8% | +13.1% | -5.8% | -3.7% | -2.3% | +6.0% |
| Dec 17 | Barclays | Maintains | Overweight → Overweight | — | $16.55 | $16.50 | -0.3% | -4.5% | -0.7% | -0.9% | +2.7% | -3.1% |
| Nov 6 | RBC Capital | Maintains | Outperform → Outperform | — | $14.37 | $14.40 | +0.2% | -2.6% | -0.7% | -1.2% | +8.2% | -3.2% |
| Nov 6 | JP Morgan | Maintains | Overweight → Overweight | — | $14.37 | $14.40 | +0.2% | -2.6% | -0.7% | -1.2% | +8.2% | -3.2% |
| Nov 6 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $14.37 | $14.40 | +0.2% | -2.6% | -0.7% | -1.2% | +8.2% | -3.2% |
| Oct 29 | Barclays | Upgrade | Underweight → Overweight | — | $14.25 | $15.24 | +6.9% | +2.9% | -3.7% | +4.1% | -5.2% | -1.7% |
| Oct 27 | RBC Capital | Maintains | Outperform → Outperform | — | $13.21 | $13.72 | +3.9% | +8.0% | -0.1% | +2.9% | -3.7% | +4.1% |
| Sep 3 | BofA Securities | Downgrade | Buy → Neutral | — | $8.55 | $8.00 | -6.4% | -2.6% | +0.5% | +2.2% | -1.6% | -1.2% |
| Sep 2 | Wedbush | Maintains | Outperform → Outperform | — | $8.13 | $8.14 | +0.1% | +5.2% | -2.6% | +0.5% | +2.2% | -1.6% |
| Aug 21 | RBC Capital | Maintains | Outperform → Outperform | — | $7.51 | $7.38 | -1.7% | -0.9% | +13.0% | -4.8% | -1.4% | +1.5% |
| Aug 7 | Wells Fargo | Maintains | Overweight → Overweight | — | $7.49 | $7.65 | +2.1% | -2.3% | -1.2% | -3.2% | +10.7% | -0.4% |
| Aug 7 | Wedbush | Maintains | Outperform → Outperform | — | $7.49 | $7.65 | +2.1% | -2.3% | -1.2% | -3.2% | +10.7% | -0.4% |
| May 8 | Barclays | Maintains | Underweight → Underweight | — | $7.99 | $7.85 | -1.8% | +10.0% | -5.2% | +5.3% | -7.5% | +0.4% |
| Feb 28 | Wells Fargo | Maintains | Overweight → Overweight | — | $14.98 | $14.98 | +0.0% | +2.5% | -5.9% | -2.1% | -1.8% | -0.4% |
| Dec 2 | Piper Sandler | Upgrade | Neutral → Overweight | — | $25.60 | $26.72 | +4.4% | +4.8% | -0.9% | -1.5% | -3.4% | +0.1% |
| Nov 8 | BMO Capital | Maintains | Outperform → Outperform | — | $23.18 | $23.01 | -0.7% | +1.9% | -1.3% | +1.7% | -0.4% | -0.5% |
| Nov 7 | JP Morgan | Maintains | Overweight → Overweight | — | $22.68 | $22.85 | +0.7% | +2.2% | +1.9% | -1.3% | +1.7% | -0.4% |
| Sep 26 | RBC Capital | Maintains | Outperform → Outperform | — | $19.76 | $20.20 | +2.2% | +3.5% | -1.0% | -0.7% | -2.3% | -0.9% |
| Aug 6 | RBC Capital | Maintains | Outperform → Outperform | — | $17.78 | $17.53 | -1.4% | +0.4% | -12.0% | +2.3% | -0.1% | -1.5% |
| Aug 6 | BMO Capital | Maintains | Outperform → Outperform | — | $17.78 | $17.53 | -1.4% | +0.4% | -12.0% | +2.3% | -0.1% | -1.5% |
| Jul 31 | JP Morgan | Maintains | Overweight → Overweight | — | $20.84 | $20.76 | -0.4% | -2.0% | -2.5% | -3.6% | -7.3% | +0.4% |
| Jun 14 | RBC Capital | Maintains | Outperform → Outperform | — | $21.31 | $21.04 | -1.3% | -3.4% | -5.2% | -0.4% | -0.4% | +2.2% |
| Jun 14 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $21.31 | $21.04 | -1.3% | -3.4% | -5.2% | -0.4% | -0.4% | +2.2% |
| Jun 14 | BMO Capital | Maintains | Outperform → Outperform | — | $21.31 | $21.04 | -1.3% | -3.4% | -5.2% | -0.4% | -0.4% | +2.2% |
| May 10 | Wedbush | Maintains | Outperform → Outperform | — | $23.54 | $23.59 | +0.2% | -4.5% | -5.1% | -4.6% | +4.6% | +5.5% |
| Apr 16 | BTIG | Maintains | Buy → Buy | — | $20.11 | $19.60 | -2.5% | -5.9% | +0.8% | -0.6% | -3.0% | -0.9% |
| Feb 28 | RBC Capital | Maintains | Outperform → Outperform | — | $26.52 | $24.47 | -7.7% | -14.1% | +0.7% | +3.8% | +0.4% | -4.5% |
| Feb 28 | BMO Capital | Maintains | Outperform → Outperform | — | $26.52 | $24.47 | -7.7% | -14.1% | +0.7% | +3.8% | +0.4% | -4.5% |
| Feb 28 | Piper Sandler | Downgrade | Overweight → Neutral | — | $26.52 | $24.47 | -7.7% | -14.1% | +0.7% | +3.8% | +0.4% | -4.5% |
| Feb 28 | Wedbush | Maintains | Outperform → Outperform | — | $26.52 | $24.47 | -7.7% | -14.1% | +0.7% | +3.8% | +0.4% | -4.5% |
| Jan 22 | Mizuho | Maintains | Buy → Buy | — | $19.64 | $19.75 | +0.6% | +1.9% | -1.4% | +0.7% | -0.2% | +1.3% |
| Nov 8 | Guggenheim | Maintains | Buy → Buy | — | $18.54 | $18.18 | -1.9% | -7.0% | -4.1% | +3.2% | -0.1% | +8.3% |
| Nov 8 | Wedbush | Maintains | Outperform → Outperform | — | $18.54 | $18.18 | -1.9% | -7.0% | -4.1% | +3.2% | -0.1% | +8.3% |
| Nov 8 | RBC Capital | Maintains | Outperform → Outperform | — | $18.54 | $18.18 | -1.9% | -7.0% | -4.1% | +3.2% | -0.1% | +8.3% |
| May 19 | BofA Securities | Maintains | Buy → Buy | — | $26.05 | $27.22 | +4.5% | +5.4% | +1.2% | +3.4% | -3.3% | -2.2% |
| May 9 | Wedbush | Maintains | Outperform → Outperform | — | $27.34 | $26.12 | -4.5% | -1.9% | +0.2% | -0.7% | +0.2% | +4.2% |
| May 9 | RBC Capital | Maintains | Outperform → Outperform | — | $27.34 | $26.12 | -4.5% | -1.9% | +0.2% | -0.7% | +0.2% | +4.2% |
| Feb 24 | Canaccord Genuity | Maintains | Buy → Buy | — | $34.18 | $34.12 | -0.2% | -3.1% | -0.8% | -2.3% | +1.2% | -3.4% |
| Feb 24 | EF Hutton | Maintains | Buy → Buy | — | $34.18 | $34.12 | -0.2% | -3.1% | -0.8% | -2.3% | +1.2% | -3.4% |
| Feb 13 | JP Morgan | Maintains | Overweight → Overweight | — | $36.95 | $37.09 | +0.4% | -2.5% | -0.4% | -1.8% | -1.1% | +1.6% |
| Feb 10 | Mizuho | Maintains | Buy → Buy | — | $36.23 | $36.20 | -0.1% | +2.0% | -2.5% | -0.4% | -1.8% | -1.1% |
| Jan 31 | EF Hutton | Maintains | Buy → Buy | — | $31.70 | $32.43 | +2.3% | +3.8% | +3.9% | +2.7% | +3.8% | +0.4% |
| Jan 30 | EF Hutton | Maintains | Buy → Buy | — | $32.50 | $32.49 | -0.0% | -2.5% | +3.8% | +3.9% | +2.7% | +3.8% |
| Dec 6 | Cowen & Co. | Maintains | Outperform → Outperform | — | $29.51 | $29.94 | +1.5% | -0.0% | +0.6% | +1.2% | -2.5% | -2.0% |
| Nov 8 | RBC Capital | Maintains | Outperform → Outperform | — | $26.96 | $27.04 | +0.3% | +8.8% | +0.6% | +3.5% | -3.5% | +0.3% |
| Oct 13 | Raymond James | Upgrade | Outperform → Strong Buy | — | $26.52 | $27.19 | +2.5% | +5.0% | -2.9% | +8.7% | -0.2% | -4.5% |
| Sep 21 | JP Morgan | Maintains | Overweight → Overweight | — | $27.61 | $28.25 | +2.3% | -2.4% | -4.4% | -3.1% | -1.4% | +1.7% |
| May 23 | Piper Sandler | Maintains | Overweight → Overweight | — | $23.55 | $23.55 | +0.0% | -3.4% | -1.3% | -1.0% | +0.6% | +1.5% |
| Feb 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $31.48 | $30.52 | -3.0% | +3.2% | -2.7% | -1.0% | -1.4% | +0.9% |
No insider trades available.
8-K · 7.01
! Medium
Xencor, Inc. -- 8-K 7.01: Regulation FD Disclosure
Xencor disclosed Phase 1 XmAb942 results and preclinical XmAb412 data via investor presentation, providing updates on its TL1A pipeline program development.
May 5
8-K · 5.02
!!! Very High
Xencor, Inc. -- 8-K 5.02: Executive Change
Xencor's executive severance policy now requires NEOs (except the CEO) to sign participation agreements to receive severance benefits, potentially affecting executive retention and compensation costs.
Apr 27
8-K · 1.02
!! High
Xencor, Inc. -- 8-K 1.02: Material Agreement Terminated
Xencor terminated a material agreement effective June 1, 2024, which could impact revenue streams or strategic partnerships and warrant investor review of the company's updated guidance and operational plans.
Mar 9
8-K · 7.01
! Medium
Xencor, Inc. -- 8-K 7.01: Regulation FD Disclosure
Xencor faces a royalty payment dispute with its Ultomiris licensee over non-U.S. sales, creating potential revenue uncertainty as the company evaluates legal and contractual remedies.
Mar 4
8-K
Xencor, Inc. -- 8-K Filing
Xencor's XmAb819 bispecific antibody progressed to Phase 1 dose expansion across multiple cancer types with Phase 3 data expected in late 2026, advancing its pipeline of T-cell engaging immunotherapies.
Feb 25
Data updated apr 27, 2026 10:38am
· Source: massive.com